Enbrel 50 MG/ML sureclickml
Ended Awarded
- Contract number
- SPE2DB26FAUAA
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $12,168
Award facts
- Contract value 100% obligated
- $12,168.32 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $12,168.32 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, for Enbrel 50 mg/ml SureClick prefilled syringes. The delivery order, issued on October 29, 2025, with an ultimate completion date of October 30, 2025, represents a single transaction under the broader Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) indefinite delivery contract. DMS Pharmaceutical Group holds a single-award IDC under PPV-G GEN V with a $499.999 billion ceiling value extending through December 31, 2036, authorizing the Defense Logistics Agency to issue firm fixed-price delivery orders for comprehensive pharmaceutical products to support Department of Defense military healthcare facilities worldwide. The award was made without a set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. Performance will occur in Conshohocken, Pennsylvania.
This delivery order exemplifies DMS Pharmaceutical Group's established role as a critical pharmaceutical supplier within the federal military medical supply chain. The company's extensive product portfolio encompasses branded and generic prescription medications, biologics, specialty pharmaceuticals, and medical consumables serving diverse therapeutic categories across Department of Defense healthcare operations. The relatively short completion timeline reflects the time-sensitive nature of pharmaceutical supply requirements for military medical facilities, with DMS Pharmaceutical Group demonstrating substantial federal contracting activity through numerous prior delivery orders issued by the Defense Logistics Agency's Medical Supply Chain division throughout October 2025.
Quick answers
Who was awarded contract SPE2DB26FAUAA?
SPE2DB26FAUAA was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on October 29, 2025.
How much is contract SPE2DB26FAUAA worth?
The government has obligated $12,168 on SPE2DB26FAUAA.
Is contract SPE2DB26FAUAA an order under another contract?
Yes. SPE2DB26FAUAA is a delivery order under SPE2DB24D2106, an indefinite delivery contract.
Was contract SPE2DB26FAUAA competed?
The extent of competition for SPE2DB26FAUAA was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award